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Abstract
Background: Low-dose primaquine is a key candidate for use in malaria transmission reduction and elimination
campaigns such as mass drug administration (MDA). Uncertainty about the therapeutic dose range (TDR) required
for general and paediatric populations challenge the implementation of the World Health Organisation’s
recommendation to add 0.25 mg/kg to current standard antimalarial treatment in such settings. Modelling work
shows that for low-dose primaquine to have an impact, high efficacy and extensive population coverage are
needed. In practice, age-based dose regimens, often used in MDA, could lead to safety concerns and a different
effectiveness profile. We aimed to define TDRs for primaquine and to assess dosing accuracy of age-based dose
regimens.
Methods: Optimised regional age-based dosing regimens for low-dose primaquine were developed in steps.
First, we identified potential TDR options based on suggested published efficacy and safety thresholds (i.e. 0.1–0.4,
0.125–0.375, 0.15–0.35 mg/kg). We then used our previously defined weight-for-age growth references and
age-based dose optimisation tool to model predicted regimen accuracies for Africa, Asia and Latin America based
on low-dose primaquine tablets (3.75 mg and 7.5 mg) currently under development by Sanofi while employing the
identified dose range options and pre-specified regimen characteristics.
Results: Dose regimens employing TDRs of 0.1–0.4 and 0.125–0.375 mg/kg had the highest average predicted dose
accuracies in all regions with the widest dose range of 0.1–0.4 mg/kg resulting in ≥99% dose accuracy in all three
regions. The narrower 0.15–0.35 mg/kg range was on average predicted to correctly dose 91.4% of the population
in Africa, 93.2% in Asia and 92.6% in Latin America. This range would prescribe ≥20% of 3-year-olds doses below 0.
15 mg/kg and ≥20% of 11-year-olds doses above 0.35 mg/kg. Widening the TDR from 0.15–0.35 to 0.1–0.4 mg/kg
increased the dose accuracy by ≥20% in Africa, ≥15% in Asia and ≥10% in Latin America.
Conclusion: Optimised age-based dose regimens derived from wider TDRs are predicted to attain the dose
accuracies required for effective MDA in malaria transmission reduction and elimination settings. We highlight the
need for a clearly defined TDR and for safety and efficacy trials to focus on doses compatible with age-based
dosing often employed in such settings.
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Background
Accurate dosing of antimalarials used in transmission-
reduction strategies such as Mass drug administration
(MDA) and Mass screening and treatment (MSaT) is
just as important as accurate prescribing in the manage-
ment of malaria patients. Underdosing with an antimal-
arial drug leads to low efficacy of the drug and renders it
ineffective to clear parasites or kill gametocytes in the
body and can be a catalyst for emergence of drug resist-
ance. Overdosing predisposes individuals to toxicity and
adverse events that may outweigh the individual benefits
of taking the drug. This has the potential to have a
significant impact on the success or failure of malaria
control and elimination programs.
Dosing based on body weight is the standard in anti-
malarial drug development. However, population-based
antimalarial mass treatment campaigns often dose indi-
viduals by their age rather than weight to avoid the need
for weighing scales. While this practice can pose a ser-
ious threat to the targeted impact of mass treatment
campaigns, the optimization and evaluation of the per-
formance of age-based dose regimens has so far received
relatively little attention. One of few studies that have
looked at age-based dose regimen of other antimalarials
in Africa, reported a high prevalence of systematic
dosing errors (only 23.5% received the target dose of SP
in children less than five years old) [1].
An antimalarial that comes highly recommended by
WHO for use in reduction transmission is primaquine
(PQ). It is licensed for the radical cure of Plasmodium
vivax malaria and has also shown gametocytocidal activ-
ity in P. falciparum. In 2010, the WHO issued a recom-
mendation to add a single dose of 0.75 mg/kg PQ to
artemisinin-based combination therapies (ACTs) in mass
treatment campaigns as a component of pre-elimination
or elimination programmes [2]. Reports that followed in-
dicated a high risk of haemolysis in glucose-6-phosphate
dehydrogenase (G6PD) deficient individuals [3]. There
was also documentation of haemolysis in non G6PD in-
dividuals who were co-administered PQ with ACT [4].
In 2012, the recommended target dose was reduced to
0.25 mg/kg and this removed the need for screening of
G6PD deficiency [3]. The single low dose PQ (LDP)
tested in G6PD individuals was slightly above and below
the recommended 0.25 mg/kg (0.4 and 0.1 mg/kg) and
no severe anaemia was observed [5]. To overcome the
practical paediatric dosing challenges in children with
the currently marketed 15 mg tablet with these altered
recommendations, Sanofi and Medicines for Malaria
Venture (MMV) are developing LDP tablets (7.5 mg and
3.75 mg) [6].
At present the WHO recommendation does not define
a therapeutic dose range (TDR) for PQ and various dose
optimization trials are still ongoing. A TDR is the
interval between the minimum efficacious dose and the
maximum tolerated dose in mg/kg body weight, based
on the available evidence. This presents the acceptable
variation in intake dose that informs the development of
safe, accurate age- and weight-based dosing regimens. A
wide TDR is better than a narrow TDR as it lowers the
potential for over- and under-dosing [1, 7]. The question
lies in how best the wide TDRs can be utilised to inform
an age-based regimen that is both safe for the commu-
nity and effective for the malaria control program. A
clearly defined, wide TDR is particularly important for
antimalarials used in mass treatment campaigns as part
of transmission reduction efforts, such as MDA or
MSaT. In these large scale population-based interven-
tions user-friendly and logistically feasible, but at the
same time accurate, dosing regimens are key. They are
essential to achieve the required intervention coverage,
drug exposure, patient adherence and dose accuracy
across the population to impact transmission.
Accurate age-based dosing requires knowledge of the
population weight-for-age (WFA) distribution across all
ages and drugs with wide TDRs. We have previously de-
veloped tools to determine optimized age-based dose
regimens using regional WFA growth references and
drug characteristics including the TDR [8, 9]. We suc-
cessfully applied them to help inform the drug ratio, tab-
let strength, and age-based dose regimen for the
artesunate-amodiaquine fixed-dose combination (Coar-
sucam™) [10]. A large pooled patient level analysis of
Coarsucam™ showed that the fixed dose combination
provided higher efficacy in all age categories, which the
investigators attributed to optimized dosing of
artesunate-amodiaquine [11].
We therefore aimed to identify different potential
TDRs for primaquine and to assess dosing accuracy of
regional age-based dose regimens for the new tablet for-
mulations using the tools described. We discuss how
these findings can help inform the required TDR for
primaquine and future dose optimization studies to
maximize the health impact of mass treatment
campaigns.
Methods
We constructed optimised regional age-based dosing regi-
mens for LDP for Africa, Asia and Latin America using
the four steps detailed below. Optimised regimens were
those age-based dose regimens with the highest predicted
dose accuracy (the proportion of recipients who will be
dosed within the assessed TDR) across all ages.
(i) Firstly, we conducted a literature review in Septem-
ber, 2015 in order to identify the TDRs for PQ from
published data. We searched online electronic databases
Medline, Embase and WHO search portal with no time
restrictions using search terms “safety and efficacy” and
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“low dose primaquine”. The inclusion criteria were stud-
ies that had assessed safety and efficacy of PQ with de-
fined TDRs. This search yielded a total of 3 studies all of
which were included in the review [12–14].
(ii) Secondly, we identified three TDRs with different
therapeutic indexes (TI) (TI = TDR upper threshold di-
vided by the TDR lower threshold) and all are symmet-
rically placed around the WHO recommended target
dose of 0.25 mg/kg. These are (i) 0.15–0.35 mg/kg, with
a narrow TI of 2.3. (ii) 0.125–0.375 mg/kg with a TI of
3. (iii) 0.1–0.4 mg/kg with a wider TI of 4. Our lowest
cut off point was 0.125 mg/kg which has been shown to
achieve maximal gametocytocidal efficacy within 24 to
48 h of administration in adults [12, 14]. Our highest cut
off point was 0.4 mg/kg. Eziefula and colleagues reported
that 0.4 mg/kg had a gametocytocidal efficacy similar to
0.75 mg/kg (mean duration of gametocyte carriage:
6.6 days in the 0.75 mg/kg group, and 6.3 days in the
0.4 mg/kg group) [13]. Doses of PQ above 0.5 mg/kg
have been associated with serious adverse events [12].
(iii) Thirdly, we developed regional WFA growth refer-
ences for malaria endemic regions, details of which are
described elsewhere [8]. Briefly, a database of over 1
million weight-for-ages from population representative
surveys in over 64 malaria endemic countries was com-
piled. We employed the previously developed extension
to the standard Generalised Additive Model for
Location, Scale and Shape (GAMLSS) to model data
from multiple sources and varying growth distributions
[9]. To increase their applicability for the optimisation of
age-based dosing of antimalarials the references were
weighted for population size at risk of falciparum or
vivax malaria [15], and integrated into a previously
developed age-based regimen optimisation tool [10].
(iv) Lastly, we employed these references and modelled
our three TDRs to assess the impact that the width of a
therapeutic range has on the predicted dose accuracy of
a regimen. We calculated the percentage of the popula-
tion predicted to receive a PQ intake dose over, under
and within the TDR using a dose optimisation tool de-
veloped within our team [10]. Predicted dose accuracies
were generated by age for a given TDR, tablet strength
and the number of dose categories in a regimen.
In our analysis we used the following restrictions
(Additional file 1: Table S1): (i) The regimen had to be a
single dose regimen. (ii) The regimen had to be based
on only two tablet strengths, i.e. a 3.75 mg ‘paediatric’
(p) and a 7.5 mg ‘adult’ (a) tablet. (iii) The regimen could
contain only dose categories of 0.5p, 1p, 1a, and 1a + 1p.
The age range was 6 months to 50 years. We set the upper
and lower therapeutic range cut-offs to 0.025 mg/kg incre-
ments. The use of tablet fractions was only allowed for the
smallest administrable dose to ensure simple user friendly
regimens appropriate for mass treatment campaigns (note
that due to the size of the tablets, the new tablets may not
be scored). We assumed a linear dose response in all age
groups.
Results
All age-based dose regimen cut-offs and their dosing ac-
curacies are presented in Table 1 below. Average dosing
accuracies for the regional optimised regimens using a
dose range of 0.15–0.35 mg/kg were: 91.4% for Africa,
93.2% for Asia and 92.6% for Latin America. The wider
0.1–0.4 mg/kg dose range had the highest average dos-
ing accuracies in all regions as follows: 99.6% for both
Africa and Asia, 99.9% for Latin America.
The modelled optimized regimen with a dose range of
0.15–0.35 mg/kg in Africa resulted in underdosing
among 3-year-olds with more than 20% receiving doses
below 0.15 mg/kg (Fig. 1). A similar proportion of 11-
year-olds would be overdosed (Fig. 1), receiving more
than 0.35 mg/kg, though most would receive a dose
between 0.125–0.375 mg/kg (Fig. 2). The highest
proportion of underdosing in Asia would be seen in the
11-year-olds (close to 18% of children) while 12-year-
olds would be overdosed in >20% of cases (Additional
file 2: Figure S1). In Latin America, ≥20% of 3- and 8-
year-olds would be over- and underdosed respectively
(Additional file 3: Figure S2).
TDRs of 0.125–0.375 mg/kg and 0.1–0.4 mg/kg resulted
in higher dosing accuracies than the 0.15–0.35 mg/kg
range (Table 1 and Additional file 4: Figure S3). On fur-
ther analysis, widening the lower and upper cut-offs of the
TDR from 0.15 to 0.1 mg/kg and 0.35 to 0.4 mg/kg re-
spectively, increased the dosing accuracy by ≥20% in Af-
rica, ≥15% in Asia, ≥10% in Latin America, with the
highest accuracy levels of ≥97% seen with the widest range
of 0.1–0.4 mg/kg across all age groups in the three regions.
Discussion
The need for antimalarial dose optimization to focus on
intervention delivery and end users is increasingly recog-
nized. This is even more important for gametocytocidal
drugs like PQ, where no direct benefit to the individual
taking the drug exists, and the risk-benefit argument is
shifted from individual to population level. Minimising
the risk of dose related adverse events in potentially
healthy individuals across the population, while achiev-
ing the high population coverage and high efficacy
across vulnerable subgroups that drives the health im-
pact of the intervention will be strongly dependent on
the implemented dose regimens.
We show that optimised age-based regional regimens
would achieve accurate dosing within the assessed TDRs in
over 90% of the population (Table 1, Fig. 1, Additional file 2:
Figure S1, Additional file 3: Figure S2 and Additional file 4:
Figure S3). The narrow TDR of 0.15–0.35 mg/kg (a TI of
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2.3) however may not be acceptable in transmission reduc-
tion and elimination treatment campaigns as a large propor-
tion of children in age categories bordering dose cut-offs
would not get a dose within the TDR (Fig. 2). With a TDR
of 0.1–0.4 mg/kg (a TI of 4) >99% of the populations in the
3 regions could be accurately dosed. As defining the TDR
for LDP is still on-going, our findings can help design future
field trials and inform discussions on the needed TDR and
TI in several ways. They highlight the benefit of optimizing
age-based regimens in contributing to dose accuracy and
likely health impact of mass treatment campaigns. They
help identify the target TDR (and TI) that needs to be
assessed and confirmed in field trials to dose ideally 100%
of a population within that range. And finally, they demon-
strate the importance for TDRs to be symmetrically placed
around the target dose for drugs that will be widely dosed
by age, a requirement that is frequently overlooked. Our
modelling methods are complementary to the more stan-
dardized pharmacokinetic-pharmacodynamic (PK-PD)
modelling techniques to assess the minimum and
maximum TDR thresholds in vulnerable subgroups as pro-
moted by the Worldwide Antimalarial Resistance Network
(WWARN) [11].
In our models, we included the vulnerable subgroup of
children. We recognise that this subgroup does not al-
ways follow a linear dose response due to differences in
pharmacokinetics within the group. The PK-PD profile
of this group can therefore follow a different pattern
from that shown in adults. However, an assumption of a
linear dose response across all age groups including
children was made in this analysis, in view of the lack of
evidence of PK-PD models of LDP in paediatric settings.
Further research is needed on this aspect.
In case-management of uncomplicated malaria the
agreed minimum acceptable level of efficacy of an anti-
malarial is 90% [16]. While this is applied to manufac-
turer regimens, WHO recommended weight-based
regimens, and other bespoke weight-based trial regi-
mens, age-based regimens are rarely assessed for their
efficacy, and national control programmes can imple-
ment various age-based dose recommendations without
ever assessing their efficacy. Similarly, there is no
consensus on the minimum expected level of either drug
efficacy or dosing accuracy for transmission reduction in
malaria elimination settings. This lack of guidance
hampers the establishment of suitable dose regimens for
Table 1 Performance of optimized PQ regimen options by region and assessed TDRs
TDR:0.125–0.375 mg/kg Africa Asia Latin America
Dose Age Accuracy Age Accuracy Age Accuracy
(tablets) (yrs) (%) (yrs) (%) (yrs) (%)
0.5p 6mo-3 97.9 6mo-4 96.1 6mo-3 97.1
1p 4–10 97.5 5–12 97.6 4–8 98.5
1a 11–16 96.4 13–16 97.7 9–13 97
1a + 1p 17+ 99.6 17+ 99.8 14+ 99.1
97.9 97.8 97.9
TDR:0.15–0.35 mg/kg Africa Asia Latin America
Dose Age Accuracy Age Accuracy Age Accuracy
(tablets) (yrs) (%) (yrs) (%) (yrs) (%)
0.5p 6mo-3 88.2 6mo-3 92 6mo-2 94.8
1p 4–10 90.3 4–11 92.9 3–8 90.3
1a 11–15 91.4 12–16 89.3 9–13 91.1
1a + 1p 16+ 95.8 17+ 98.6 14+ 94
91.4 93.2 92.6
TDR:0.1–0.4 mg/kg Africa Asia Latin America
Dose Age Accuracy Age Accuracy Age Accuracy
(tablets) (yrs) (%) (yrs) (%) (yrs) (%)
0.5p 6mo-4 99.3 6mo-4 99.4 6mo-3 100
1p 5–11 99.7 5–12 99.6 4–9 99.6
1a 12–16 99.3 13–19 99.5 10–14 99.8
1a + 1p 17+ 100 20+ 100 15+ 100
99.6 99.6 99.9
0.5p = 1.875, 1p = 3.75 mg, 1a = 7.5 mg, 1a + 1p = 11.25 mg, PQ Primaquine, MO months. TDR Therapeutic Dose Range
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MDA campaigns employed in such settings. Age-based
regimens with overall dose accuracy over 90% that
significantly over- and underdose particular age groups
can be evaluated on their suitability and effectiveness to
control transmission in targeted efficacy studies (e.g. by
assessing the efficacy in those specific age and weight sub-
groups predicted to receive doses below the TDR) before
they are assessed in large scale population trials. The use
of targeted safety studies and pharmacovigilance in sub-
groups who receive intake doses above the upper TDR
threshold (particularly individuals in the age categories
bordering dose cut-offs) could also help accumulate key
safety data in a short-period and help define practical regi-
mens and acceptable dosing levels for populations.
By visualizing the loss in dosing precision with age-
based dosing at population level, we call for a more
careful review by policy makers and control programme
managers to balance the risks and benefits of age-based
versus weight-based dosing in programmes directed at
reducing malaria transmission. While weight-based doses
Fig. 1 Comparison of dosing accuracy for modelled dose ranges in Africa. Population under (red), over (blue) and correctly (white) dosed by age for
Africa using three dose ranges (0.1–0.4, 0.125–0.375 and 0.15–0.35 mg/kg). PQ = Primaquine, TDR = Therapeutic dose range, tab = tablet strength
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pose considerable logistical challenges due to the need for
and maintenance of large numbers of weighing scales, these
should be carefully reviewed against any predicted or
unknown health impact and safety concerns with the iden-
tified TDRs and associated age-based dosing regimens.
One of the main strengths of our study is that we have
utilised the tablet sizes and strengths that are already
established on the market which makes it easier for fu-
ture studies to implement. Our study explores the dose
range that can be used in relation to the tablet size and
strength. However, the concept is not limited to the tab-
lets used in this study. It can be applied to other future
tablet sizes and strengths should they be developed. An-
other strength lies in the fact that the age-based dose
regimen of each region reflects its population as it is
based on each region’s weight for age growth references.
Our model is limited in that it does not take into ac-
count how the safety margins of LDP may shift in G6PD
deficient individuals. Currently, there are no guidelines of
how to adapt the dosing in the variants of G6PD defi-
ciency, especially taking into account that PQ causes a
dose-dependent haemolysis [17]. Wickham et al., reports
that LDP that was shown to be safe in African G6PD defi-
cient individuals was shown to induce haemolysis in
Mediterranean variant of G6PD in a mouse model [18].
Therefore, the difficulty will be in determining the lower
safety margin and risk of underdosing in the African vari-
ant of G6PD. On the other hand, the upper safety margin
and the risk of overdosing in Mediterranean variant of
G6PD will need to be established. Further studies on the
safety margins of LDP in G6PD deficient individuals will
need to be conducted in order to get an accurate picture.
Conclusions
In conclusion, our findings highlight the potential
impact on the expected dose accuracy with shift in the
agreed TDR and the need for clearly established mini-
mum width of the TDR through safety and efficacy
studies. This needs to be assessed with the feasibility of
age-based dosing of single low dose PQ to reduce trans-
mission of malaria. This principle is further relevant for
any drug with an age-based dose regimen.
Additional files
Additional file 1: Table S1. Modelled regimen characteristics. Summary
of the regimen characteristics used in the models. (DOCX 11 kb)
Additional file 2: Figure S1. Comparison of dosing accuracy for
different therapeutic dose ranges in Asia. Population under (red), over
(blue) and correctly (white) dosed by age for Africa using three dose
ranges (0.1–0.4, 0.125–0.375 and 0.15–0.35 mg/kg). PQ = Primaquine,
TDR = Therapeutic dose range, tab = tablet strength. (TIFF 117 kb)
Fig. 2 Predicted intake dose for selected body weight centiles by age for Africa, Asia and Latin America using a dose range of 0.15–0.35 mg/kg.
Proportion of the population in the three regions predicted to receive doses between 0 and 15-0.35 mg/kg (tab = 3.75 mg) by age for PQ, black
triangle indicates regimen cut-offs on the horizontal axis as follows: Africa = 6 months (mo)-3, 4–10, 11–15 and 16+ years; Asia =6mo-3, 4–11, 12–
16 and 17+ years; Latin America = 6mo-2, 3–8, 9–13 and 14+ years
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Additional file 3: Figure S2. Comparison of accuracy for different
therapeutic dose ranges in Latin America. Population under (red), over
(blue) and correctly (white) dosed by age for Africa using three dose
ranges (0.1–0.4, 0.125–0.375 and 0.15–0.35 mg/kg). PQ = Primaquine,
TDR = Therapeutic dose range, tab = tablet strength. (TIFF 130 kb)
Additional file 4: Figure S3. Predicted dose intake for selected body
weight centiles by age for Africa, Asia and Latin America. Proportion of the
population in the three regions predicted to receive doses between 0.1–
0.4 mg/kg (plane dotted line) and 0.125–0.375 mg/kg (bold dotted line) by
age for Primaquine, black triangle indicates regimen cut-offs on the
horizontal which for the 0.1–0.4 mg/kg range translated to the following
regimen cut offs: Africa = 6 months (mo) -4, 5–11, 12–16 and 17+ years; Asia
=6mo-4, 5–12, 13–19 and 20+ years; Latin America = 6mo-3, 4–9, 10–14
and 15+ years. A similar illustration for the 0.125–0.375 mg/kg resulted in
the following regimen cut-offs: Africa = 6 months (mo) -3, 4–10, 11–16 and
17+ years; Asia =6mo-4, 5–12, 13–16 and 17+ years; Latin America = 6mo-3,
4–8, 9–13 and 14+ years. (TIFF 120 kb)
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